Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Neuro-Oncology New Patient Coordinator
CONTACT
Lead
Nicholas Butowski
With
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of intratumoral administration of SRN-101 in participants with recurrent high-grade glioma (rHGG) undergoing resection. II. To evaluate the biologic activity of SRN-101. EXPOLORATORY OBJECTIVES: I. To assess immunologic response to SRN-101. II. To identify potential pharmacodynamics biomarkers for SRN-101 activity. OUTLINE: Participants will receive a single administration of SRN-101 during real-time magnetic resonance imaging (MRI)-guided convection-enhanced delivery (CED), followed by non-investigational surgical resection 7 to 21 days after SRN-101 administration. Participants will be followed for up to 5 years after surgical resection.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted